Healthcare Services Group
- Market cap
- 1.43B
- P/E (TTM)i
- 12.16
- P/Bi
- 2.75
- EPSi
- 0.81
- Div yieldi
- 0.00%
- 52W posi
- 52%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Fair Value how this is computed
- Implied fair-value range of 8.44-41.43, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -16.6% below the average-multiple fair value of 24.94.
Valuation each multiple against its own 5-year range
Vs. peers Medical Care Facilities
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Healthcare Services Group (HCSG) | 1.43B | 12.16 | 2.75 | 0.00% |
| HCA Healthcare (HCA) | 95.08B | 14.73 | -14.32 | 0.68% |
| Tenet Healthcare (THC) | 20.92B | 10.04 | 4.49 | 0.00% |
| Encompass Health (EHC) | 12.08B | 19.95 | 4.65 | 0.62% |
| DaVita (DVA) | 11.28B | 14.57 | -14.74 | 0.00% |
| Fresenius Medical Care (FMS) | 11.01B | 11.14 | 0.78 | 4.13% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 7.2% above Morningstar's fair value estimate.
Fair value
Healthcare Services Group Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% premium over our quantitative fair value estimate of $19.30 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The firm's unfavorable dividend structure undermines our quantitative valuation. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. Reflecting the firm's dividends is its forward dividend yield of 0%, which falls in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are expensive.
Alternatively, the firm's valuation metrics are reassuring. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's price to cash ratio of 8.5, for example, sits in the top 50% compared with peers globally. While the liquidation value can be important for some businesses, we don't believe this is one of them. The low cash balance relative to the firm's market value could signal heavy reinvestment for growth. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.
By Quantitative Equity Report
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.